FibrosisLab
Article
2025-12-09

The Roadmap to MASH Complete Remission: Cracking the 'Monotherapy Ceiling' with Combination Therapy

Resmetirom alone: 25% fibrosis improvement. Semaglutide: 37%. The majority DON'T improve. The answer? Combination therapy. We map out the optimal FGF21 + GLP-1 + THR-β combos for the Post-Monotherapy era.

Monotherapy Doesn't Cure Most Patients—That's the Reality

Resmetirom and Semaglutide have arrived, but let's be blunt: fibrosis improves in only 25-37% of patients. The majority remain unimproved.

The key to breaking this ceiling is Combination Therapy. This article maps out the ideal drug pairings—FGF21 analogs with Resmetirom or GLP-1—and charts the roadmap to MASH complete remission.

The Ideal Partnership: Concrete Combination Strategies

We aim for synergistic effects by combining drugs with different mechanisms of action.

1. GLP-1 (Metabolic Backbone) + Anti-fibrotic Agent

Currently, this is a strategy viewed as promising primarily at the theoretical and early trial levels, and multiple combination trials combining GLP-1 agents with Resmetirom or FGF21 analogs are underway.

  • Theoretical Background: Manage systemic weight and metabolism with GLP-1 receptor agonists (Semaglutide, Tirzepatide) to cut off the "fuel (fatty acid) supply" to the liver. On top of that, directly strike the remaining intrahepatic inflammation and fibrosis signals with liver-specific agents like Resmetirom. This is a fusion of "defense and offense."
  • Expected Effects: Dramatic improvement in fibrosis improvement rates, long-term maintenance of MASH resolution, and suppression of liver cancer development.

2. Incretin Combinations (GLP-1 based combinations)

  • GLP-1/GIP (Tirzepatide): It has already produced strong data, but attention is focused on how its metabolic improvement effects, which surpass Semaglutide, will impact the liver.
  • GLP-1/Glucagon (Survodutide, etc.): Adds the energy expenditure enhancing effect of glucagon. It has been reported that over 60% of patients achieve a liver fat reduction of 30% or more, suggesting it could be a powerful "fat reduction driver" potentially surpassing GLP-1 monotherapy in MASH resolution and fibrosis improvement.

Leading Actors in the Pipeline: The Rise of FGF21 Analogs

Following THR-β and GLP-1, FGF21 (Fibroblast Growth Factor 21) analogs are rapidly increasing their presence as the third pillar.

Pegozafermin (89bio) / Efruxifermin (Akero)

  • Mechanism of Action: FGF21 is a metabolic regulatory hormone produced in the liver. Administration is believed to improve lipid metabolism and insulin sensitivity, as well as have direct anti-fibrotic effects.
  • ENLIVEN Trial (Pegozafermin): In a Phase 2b trial, a fibrosis improvement rate of 27% (vs. placebo 7%) was achieved in the F2-F3 patient group. Particular attention is being paid to safety and additive effects in combination trials with GLP-1 receptor agonists.
  • Characteristics: Unlike GLP-1, it can improve liver fat and fibrosis without accompanying significant weight loss, making it a viable option for patients who do not desire appetite suppression or non-obese MASH patients.

Diagnosis Revolution: Evolution of Biomarkers (NITs)

The evolution of therapeutics requires the evolution of diagnostic technologies. The shift from painful "liver biopsies" to blood tests and imaging diagnostics (NITs) is becoming decisive.

  • FIB-4 Index: Basic screening. Essential for "pick-up" in primary care.
  • ELF Score / PRO-C3: Markers to see the "activity" or "dynamic change" of fibrosis. Validation is currently underway in programs like the FDA's Biomarker Qualification Program, and future use for enrichment in trial designs and evaluation of treatment response is expected.
  • VCTE (FibroScan): Evaluation by Liver Stiffness Measurement (LSM) is seeing movement towards acceptance by the FDA as a "reasonably likely surrogate endpoint" in MASH trials, making the departure from biopsy dependence a reality.
  • MRE (MR Elastography): A "gold standard class" modality for non-invasively evaluating liver stiffness, increasingly adopted as an endpoint in many clinical trials.

Conclusion: Towards Precision Medicine

Towards 2030, MASH treatment will evolve from a one-size-fits-all approach to precision medicine.

  • Patients with Obesity Preponderance → GLP-1/GIP agents
  • Non-obese Patients with Liver Pathology Preponderance → Resmetirom
  • Patients with Advanced Fibrosis → Combination Therapy (GLP-1 + Resmetirom / Pegozafermin)

The arrival of two approved drugs is not the goal, but merely the first piece to solving this complex puzzle. We are now standing at the entrance of an exciting era towards overcoming MASH.